Many groundbreaking scientific discoveries never reach patients because they fail to attract capital or secure a commercial partnership. This "translation death" highlights that business development, not just R&D, is a critical bottleneck in delivering therapies to patients.
By outsourcing development and maintaining a core team of only nine people, MediciNova advances a late-stage CNS asset with a $12-13 million annual burn—a figure many biotechs spend quarterly. This ultra-lean model minimizes shareholder dilution while pursuing a high-value program.
MediciNova's drug MN-166 (ibudilast) has a distinct mechanism that doesn't target the motor neuron itself. Instead, it dials down neuroinflammation and over-activated glial cells. This creates a less toxic, more protective environment, improving the neuron's chances of survival.
Since the failure and market withdrawal of Relyvrio, regulators now require a higher standard of evidence for ALS drugs. A marginal signal is insufficient; companies must show a clear, coherent story across function, survival, and biomarkers to gain approval and convince payers.
While a pivotal trial proves causation for regulators, an expanded access study plays a complementary role. It adds 'texture' by gathering real-world safety and biomarker data in a broader patient population, reinforcing the regulatory and commercial story without substituting for controlled evidence.
Pharma's renewed interest in neuroscience is not for early-stage discovery. They are underwriting late-stage, de-risked assets with human proof-of-concept, understood mechanisms, and biomarker data. This strategy allows them to buy optionality on validated programs while avoiding the high cost of early failures.